Edge Therapeutics®, Inc. is a clinical-stage biotechnology company that discovers, develops and seeks to commercialize novel, hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening neurological and other conditions.

We are currently evaluating EG-1962, our lead product candidate, in the Phase 3 NEWTON 2 study in adult patients with aneurysmal subarachnoid hemorrhage (aSAH). This study will evaluate EG-1962’s ability to improve patient outcomes versus standard of care oral nimodipine after an aSAH resulting from a ruptured brain aneurysm.

Our product candidates utilize our proprietary Precisa™ development platform, a novel delivery approach that seeks to enable targeted and sustained drug exposure at the site of injury, while potentially avoiding off-target side effects associated with systemic delivery.

“At Edge, our primary goal is to save lives around the world by developing therapies for serious, unmet medical conditions in the hospital setting. This purpose drives our strategy and our work each and every day.”Brian Leuthner
President and CEO